AXA Investment Managers’s Ionis Pharmaceuticals IONS Stock Holding History

AXA Investment Managers’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$26.6M	Buy	+406,451	New	+$19.8M	0.07%	242

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AXA Investment Managers's IONS Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Ionis Pharmaceuticals (IONS) in Q3 2025: 406,451 shares worth $26.6M. The stake represents 0.07% of the portfolio and ranks #242 among its holdings.

435 funds tracked by Wall St. Rank hold IONS as of Q3 2025.

AXA Investment Managers held 406,451 shares of Ionis Pharmaceuticals worth $26.6M as of Q3 2025.
Ionis Pharmaceuticals was a new AXA Investment Managers position in Q3 2025.
Ionis Pharmaceuticals made up 0.07% of AXA Investment Managers's portfolio in Q3 2025, its #242 holding.
435 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.